Resveratrol nanoparticle pretreatment improved the oral bioavailability of bromocriptine: Involvement of liver and intestinal CYP3A enzyme inhibition

Background: Resveratrol (RSV) is a polyphenol belonging to phytoalexin family and has been reported to show inhibitory effects on CYP3A4 enzymes. However, there has been no report about the pharmacokinetic interaction of bromocriptine (BRO) with RSV and RSV nanoparticles (NRSV) in rats. Hence, the p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of natural science, biology and medicine biology and medicine, 2019-07, Vol.10 (2), p.209-216
Main Authors: Neerati, Prasad, Palle, Suresh
Format: Article
Language:English
Subjects:
Animals
Bioavailability
Bromocriptine
Chemical properties
Cytochrome
Cytochrome P-450
Drug dosages
Drug interactions
Enzymes
Family
Health aspects
Intestinal absorption
Intestine
Laboratories
Liver
Metabolism
Metabolites
Microsomes
Morphology
Nanoparticles
Particle size
Pharmacological research
Pharmacology, Experimental
Physiological aspects
Phytoalexins
Phytochemicals
Resveratrol
Small intestine
Studies
Type 2 diabetes
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Resveratrol (RSV) is a polyphenol belonging to phytoalexin family and has been reported to show inhibitory effects on CYP3A4 enzymes. However, there has been no report about the pharmacokinetic interaction of bromocriptine (BRO) with RSV and RSV nanoparticles (NRSV) in rats. Hence, the present study was undertaken in an attempt to enhance the oral bioavailability of BRO when BRO was pretreated with RSV and NRSV. Materials and Methods: Antisolvent precipitation method is used to prepare NRSV under temperature control. The following methods were used in this study, i.e., in vitro assessment of CYP3A activity in liver and intestinal microsomes and in vitro noneverted sac method. To confirm the in vitro findings, an in vivo pharmacokinetic study was also performed. Results: The results indicate that RSV significantly (P < 0.05) inhibited the CYP3A activity in intestinal and liver microsomes. In noneverted sac study, the intestinal transport and Papp of BRO were more significant (P < 0.05) in NRSV as compared to RSV group. Further, in vivo study revealed that the increased levels of Cmax and AUC were comparatively higher in NRSV-pretreated group than RSV group. In addition, pretreatment with RSV and NRSV significantly (P < 0.05) decreased the mean appararant clearance (CL/F) of BRO. Conclusion: NRSV pretreatment significantly increased the intestinal absorption and bioavailability of BRO probably by the inhibition of CYP3A-mediated metabolism in rats. However, further studies are needed to confirm these interactions in humans.
ISSN:0976-9668
2229-7707
DOI:10.4103/jnsbm.JNSBM_126_19